BMS-986256 + mycophenolate mofetil

**BMS-986256 + mycophenolate mofetil** is an investigational combination therapy studied in the context of autoimmune diseases, particularly systemic lupus erythematosus (SLE). BMS-986256 (also known as afimetoran) is a potent, selective, oral small molecule inhibitor of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8), which are implicated in mediating inflammatory responses to self- and pathogen-associated RNA. By inhibiting these endosomal receptors, BMS-986256 aims to reduce aberrant immune activation that is characteristic of diseases like lupus, leading to decreased production of inflammatory cytokines such as IL-6 and altered immune cell activation[1][3]. Mycophenolate mofetil is an orally administered immunosuppressant used as a standard-of-care therapy in autoimmune disorders, acting as an inhibitor of inosine monophosphate dehydrogenase, thereby blocking de novo guanosine nucleotide synthesis in lymphocytes and inhibiting proliferation of T and B cells. The combination is under clinical investigation for its potential synergistic immunomodulation to better control disease activity in lupus and related conditions[2][6].